TALEN-mediated generation and genetic correction of disease-specific human induced pluripotent stem cells

Current Gene Therapy

Volumn 14, Issue 6, 2014, Pages 461-472

  Ramalingam, Sivaprakash ^a   Annaluru, Narayana ^a   Kandavelou, Karthikeyan ^b   Chandrasegaran, Srinivasan ^a  

^a The Johns Hopkins University   (United States)

^b PONDICHERRY ENGINEERING COLLEGE   (India)

Author keywords

Cystic fibrosis (CF); Gaucher s disease (GD); Gene correction; Sickle cell disease (SCD); Transcription activatorlike effector nucleases (TALENs); Zinc finger nucleases (ZFNs)

Indexed keywords

CCR5 PROTEIN, HUMAN; CFTR PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDONUCLEASE; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; HEMOGLOBIN;

ANEMIA, SICKLE CELL; CELL CULTURE; CELL DIFFERENTIATION; CYSTIC FIBROSIS; CYTOLOGY; FIBROBLAST; GAUCHER DISEASE; GENE THERAPY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE;

ANEMIA, SICKLE CELL; BASE SEQUENCE; CELL DIFFERENTIATION; CELLS, CULTURED; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDONUCLEASES; FIBROBLASTS; GAUCHER DISEASE; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HEMOGLOBINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTORS, CCR5; REGENERATIVE MEDICINE;

EID: 84924815684     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666140918101725     Document Type: Article

References (47)

1. [1] Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: Zinc finger fusions to FokI cleavage domain. Proc Natl Acad Sci USA 1996; 93: 1156-60.
2. [2] Bibikova M, Carroll D, Segal DJ, et al. Stimulation of homologous recombination through targeted cleavage by a chimeric nuclease. Mol Cell Biol 2001; 21: 289-97.
3. [3] Ramalingam S, Kandavelou K, Rajenderan R, et al. Creating designed zinc finger nucleases with minimal cytotoxicity. J Mol Biol 2011; 405: 630-41.
4. [4] Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823-6.
5. [5] Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819-23.
6. [6] Yanik M, Alzubi J, Lahaye T, et al. TALE-PvuII fusion proteins--novel tools for gene targeting. PLoS One 2013; 8: e82539.
7. [7] Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003; 300: 763.
8. [8] Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435: 646-51.
9. [9] Kandavelou K, Mani M, Durai S, et al. Targeted manipulation of mammalian cells using designed zinc finger nucleases. Biochem Biophy Res Commun 2010; 388: 56-61.
10. [10] Zou J, Rashid ST, Strick-Marchand H, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011; 118: 4599-608.
11. [11] Sabastiano V, Maeder ML, Angstman JF, et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 2011; 29: 1717-26.
12. [12] Ramalingam S, Kandavelou K, London V, et al. Generation and genetic engineering of human induced pluripotent stem cells using designed Zinc finger nucleases. Stem Cells Dev 2013; 22: 595-610.
13. [13] Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of _1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011; 478: 391-4.
14. [14] Zou J, Sweeney CL, Chou BK, et al. Oxidase deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease mediated safe harbor targeting. Blood 2011; 117: 5561-72.
15. [15] Hockemeyer D, Soldner F, Beard C, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zincfinger nucleases. Nat Biotechnol 2009; 27: 851-7.
16. [16] Hockemeyer D, Wang H, Kiani S, et al. Genetic Engineering of human pluripotent cells using TALE nucleases. Nat Biotech 2011; 29: 731-4.
17. [17] Choi SM, Kim Y, Shim JS, et al. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 2013; 57: 2458-68.
18. [18] Sun N, Zhao H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng 2014; 111: 1048-53.
19. [19] Christian M, Cermak T, Doyle EL, et al. Targeting DNA doublestrand breaks with TAL effector nucleases. Genetics 2010; 186: 757-61.
20. [20] Beumer KJ, Trautman JK, Christian M, et al. Comparing zinc finger nucleases and transcription activator-like effector nucleases for gene targeting in Drosophila. G3 (Bethesda) 2013; 3: 1717-25.
21. [21] Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrasedefective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298-306.
22. [22] Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc finger nucleases. Nat Biotechnol 2008; 26: 808-16.
23. [23] Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28: 839-47.
24. [24] Ye L, Chang JC, Lin C, et al. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci U S A 2009; 106: 9826-30.
25. [25] Chang JC, Ye L, Kan YW. Correction of the sickle cell mutation in embryonic stem cells. Proc Natl Acad Sci U S A 2006; 103: 1036-40.
26. [26] Wu LC, Sun CW, Ryan TM, et al. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 2006; 108: 1183-8.
27. [27] Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318: 1920-3.
28. [28] Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294: 2368-71.
29. [29] Panicker LM, Miller D, Park TS, et al. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci U S A 2012; 109: 18054-9.
30. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin HbS allele and sickle cell disease: A HuGE review. Am J of Epidemiology 2000; 151: 839-45.
31. [31] Mali P, Chou BK, Yen J, et al. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells 2010; 28(4): 713-20.
32. [32] Sun N, Liang J, Abil Z, Zhao H. Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. Mol Biosyst 2012; 8: 1255-63.
33. [33] Ng ES, Davis RP, Azzola L, et al. Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood 2005; 106: 1601-3.
34. [34] Gabriel R, Lombardo A, Arens A, et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nature Biotech 2011; 29: 816-23.
35. [35] Ye L, Chang JC, Lin C, et al. Generation of induced pluripotent stem cells using site-specific integration with phage integrase. Proc Natl Acad Sci U S A 2010; 107: 19467-72.
36. [36] Karow M, Chavez CL, Farruggio AP, et al. Site-specific recombinase strategy to create induced pluripotent stem cells efficiently with plasmid DNA. Stem Cells 2011; 29: 1696-704.
37. [37] Li X, Burnight ER, Cooney AL, et al. Piggybac transposase tools for genome engineering. Proc Natl Acad Sci U S A 2013; 10: E2279-87.
38. [38] Yang L, Guell M, Byrne S, et al. Optimization of scarless human stem cell genome editing. Nucleic Acids Res 2013; 41: 9049-61.
39. [39] Fu Y, Foden JA, Khayter C, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 2013; 31: 822-26.
40. [40] Cradick TJ, Fine EJ, Antico CJ, Bao G. CRISPR/Cas9 systems targeting _-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 2013; 41(20): 9584-92.
41. [41] Campbell JM, Hartjes KA, Nelson TJ, et al. New and TALENted Genome Engineering Toolbox. Circ Res 2013; 113: 571-87.
42. [42] Ding Q, Lee YK, Schaefer EA, et al. A TALEN genome editing system for generating human stem cell-based disease models. Cell Stem Cell 2013; 12: 238-51.
43. [43] Schwank G, Koo BK, Sasselli V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of Cystic Fibrosis patients. Cell Stem Cell 2013; 13: 653-8.
44. [44] Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013; 342: 253-7.
45. [45] Zou S, Glynn S, Kuritzkes D, et al. Hematopoietic cell transplantation and HIV cure: Where we are and what next? Blood 2013; 122: 3111-15.
46. [46] Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370: 901-10.
47. [47] Kay MA, Walker BD. Engineering cellular resistance to HIV. N Engl J Med 2014; 370: 968-9.